GC Cell Corporation (144510.KQ)
KOSDAQ · KRW · Healthcare · Diagnostics & Research
₩11,610 (-10.36%) as of
Key statistics
- Market cap
- 174.47B
- Dividend yield
- 0.00%
- 52-week range
- 11,520.00 – 28,450.00
- Beta
- 0.57
- Revenue (TTM)
- 162B
- Profit margin
- -152.10%
- Volume
- 8.17k
About GC Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Yongin-si, South Korea
- Employees
- 674
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.